Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.
Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.
Adding a gonadotropin-releasing hormone analog to cyclophosphamide-containing chemotherapy significantly reduces the risk for premature ovarian insufficiency in premenopausal women with breast cancer, Chinese research shows.
The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.
The pan-nitric oxide signaling inhibitor NG-monomethyl-l-arginine in combination with taxane merits further investigation in the locally advanced or metastatic triple-negative breast cancer setting, say researchers.